News

GLISTEN AASLD-presented data show linerixibat reduces biomarkers and itch in PBC, supporting the drug as an ileal bile acid transporter inhibitor.

In this interview with Nguyen, Nguyen highlights takeaways from From 'Basement Membrane to Bedside: The Science & Strategy of Bullous Diseases.'

Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

At ACAAI 2025, Harris discussed research on novel mechanism known as allergic effector cell response inhibitors.

A study presented at AASLD 2025 shows patients with alcohol-associated liver disease experience greater stigma compared with non-ALD patients.

Younossi explains the importance of patient-reported outcomes and assessing HRQoL, breaking down findings from an analysis of the MAESTRO-NAFLD trial of resmetirom.

ELATIVE 3-year open-label extension data show sustained reductions in pruritus and fatigue in adults with primary biliary cholangitis treated with elafibranor.

Kremer describes recent advancements in the PBC treatment landscape and reviews findings from abstracts on elafibranor presented at AASLD The Liver Meeting 2025.

ALTUS findings presented at AASLD show mt-HBT detects early-stage HCC with >66% higher sensitivity than ultrasound, addressing gaps in liver cancer surveillance.

In a phase 3 NATRON trial presented at ACAAI 2025, Ogbogu discussed how benralizumab reduced flare in patients with hypereosinophilic syndrome.

In this segment of his SDPA Fall interview, Nguyen highlighted his second talk ‘Patterns in Red and Purple: Decoding Vasculitis in the Skin.’

Although the initial MACE composite outcome was not statistically significant, investigators saw follow-up MI risk reduced by >50%.

Bowlus explains clinical outcomes associated with PBC and the importance of assessing liver stiffness over time, highlighting data on seladelpar from AASLD.

AASLD-presented data show HCCs persist after weight or diabetes control, with a new target of fibrotic immune phenotype to prevent MASH-related complications.

The SGLT2 inhibitor also displayed its efficacy in reducing left ventricular myocardial fibrosis and volume, as well as improving diastolic filling dynamics.

At ACAAI 2025, Golden discussed how mild local reactions and expected systemic effects support the sublingual film’s strong safety profile in children.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

This interview features Nguyen discussing his SDPA talk titled ‘The Itch Within: Immune Pathways Driving Chronic Spontaneous Urticaria.’

The analysis of data from a single-source rare disease specialty pharmacy sheds light on high treatment adherence and low discontinuation of Cuvrior.

Acute kidney injury mortality rises in wealthier nations, highlighting urgent need for targeted prevention strategies.

Clark reviews findings from a 3-year longitudinal study comparing VCTE to liver biopsy for staging F2/F3 fibrosis in patients with AATD liver disease.

Children achieved therapeutic epinephrine levels within 2 minutes on AQST-109 (Anaphylm), showing an early cardiovascular response similar to adults.

AASLD 2025 data show mazdutide significantly reduces liver fat, ALT, AST, and insulin resistance in patients with obesity, and MASLD

Data from the DECAF study suggests caffeine may have a slightly beneficial effect on AF recurrence, although investigators urge caution in interpretation.

Findings showed elafibranor led to expression changes of proteins linked to fatigue or mitochondrial function, significantly correlated with each other and with fatigue improvement.

Data presented at AASLD 2025 hepatitis delta patients experience significant physical and emotional challenges, emphasizing the need for holistic care approaches and screening beyond risk-based recommendations.

Navar discusses the groundbreaking results of this phase 3 trial, as well as the implications of an oral PCSK9 inhibitor for treatment adherence and persistence.